Business Context and Reporting Period
This Form 8-K was filed by Tango Therapeutics, Inc. (TNGX) on August 30, 2023, reporting events occurring on August 28, 2023. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
- Resignation: Aaron Davis resigned from the Board of Directors effective immediately on August 28, 2023. The departure was not due to any disagreement with management or the Board.
- Appointment: John Ketchum was appointed as a Class III director effective August 29, 2023, to fill the vacancy. He is considered independent under Nasdaq listing standards.
Guidance, Outlook, and Compensation
There is no financial guidance or operational outlook provided in this filing. The document details the compensatory arrangements for the new director, Mr. Ketchum:
- Equity Awards: A stock option to purchase 60,000 shares at an exercise price of $7.19 (vesting monthly over 3 years) and a restricted stock unit (RSU) award for 10,000 shares (vesting annually over 3 years).
- Cash Compensation: An annual retainer of $40,000.
- Conditions: Vesting for both equity awards ceases if Mr. Ketchum stops serving on the Board.
Investor Verification Checklist
- Verify the independence status of John Ketchum in subsequent proxy statements.
- Review the Company's 10-Q or 10-K for the most recent financial position, as this 8-K contains no financial data.
- Confirm the vesting schedule and exercise price of the new director's equity awards against the Company's stock price at the time of grant.